HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Kondili, Loreta A.; Weimer, Le; Mallano, Alessandra; Fucili, Luca; Massella, M; Vinci, M.; Borgia, Guglielmo; Brunetto, M.R.; Surace, L.; Gaeta, G.B.; Chemello, Liliana; Andreone, Pietro; Raimondo, Giovanni; Filomia, Roberto; Persico, Marcello; Puoti, Massimo; Rumi, M.G.; Benedetti, A.; Ieluzzi, Donatella; Nardone, Gerardo; Giuseppe, F Di; Ciancio, Alessia; Taliani, G.; Biliotti, Elisa; Madonia, S.; Stagno, B; Alberti, Alberto; Massari, Marco; Rosina, F.; Mazzella, Giuseppe; Leo, A Di; Iannone, Anna; Ferrari, Carlo; Orlandini, A.; Monti, M.; Santantonio, T.; Chessa, Luchino; Erne, Em; Coppola, Carmine; Andreoni, M; Baldelli, Franco; Mondelli, Mario U.; Blanc, Pierluigi; Gasbarrini, Antonio; Verucchi, G; Colombo, Massimo; Borghi, Marta; Craxı̀, Antonio; Petta, Salvatore; Villa, Erica; Patti, O.; Russo, F.P.; Strazzabosco, Mario; Vella, Stefano; Zignego, Anna Linda

doi:10.1016/s0168-8278(16)01149-1

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only two (17%) patients experienced serious adverse events. Very recently, in a nationwide Italian study, Kondili et al reported the disappearance or improvement of more than 50% of CryoVas symptoms in 31/37 (84%) patients after DAA, with no specific details on kidney parameters [78]. A Canadian group described eleven patients with symptomatic HCV-CryoVas who received IFN-free DAA combinations (mean age of 56 years old, 61% females, 57% cirrhotics) [79].…”

Section: The Particular Case Of Hcv Cryoglobulinemia Vasculitis With mentioning

confidence: 99%

Hepatitis C virus infection and chronic kidney disease: Time for reappraisal

Cacoub

Desbois

Isnard-Bagnis

et al. 2016

Journal of Hepatology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is associated with tremendous morbidity and mortality due to liver complications. HCV infection is also associated with many extrahepatic manifestations including cardiovascular diseases, glucose metabolism impairment, cryoglobulinemia vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease (CKD). Many studies have shown a strong association between HCV and CKD, by reporting (i) an increased prevalence of HCV infection in patients on haemodialysis, (ii) an increased incidence of CKD and proteinuria in HCV-infected patients, and (iii) the development of membranoproliferative glomerulonephritis secondary to HCV-induced cryoglobulinemia vasculitis. HCV seropositivity is found to be associated with an increased relative risk for all-cause and cardiovascular mortality in the dialysis population. HCV seropositivity is linked to lower patient and graft survival after kidney transplantation. Such poor HCV-associated prognosis should have encouraged clinicians to treat HCV in CKD patients. However, due to frequent side effects and the poor efficacy of interferon-based treatments, very few HCV dialysis patients have received HCV medications until now. The emergence of new direct acting, interferon-free antiviral treatment, leading to HCV cure in most cases with a satisfactory safety profile, will shortly modify the management of HCV infection in CKD patients. In patients with a glomerular filtration rate (GFR) >30ml/min, the choice of DAA is not restricted. In those with a GFR <30 and >15ml/min, only paritaprevir/ritonavir/ombitasvir/dasabuvir or a grazoprevir plus elbasvir regimen are approved. In patients with end stage renal disease (GFR <15ml/min or dialysis), current data only allows for the use of a grazoprevir plus elbasvir combination. No doubt these data will be modified in the future with the advent of new studies including larger cohorts of HCV patients with renal impairment.

show abstract

Section: The Particular Case Of Hcv Cryoglobulinemia Vasculitis With mentioning

confidence: 99%

Hepatitis C virus infection and chronic kidney disease: Time for reappraisal

Cacoub

Desbois

Isnard-Bagnis

et al. 2016

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…Only 2 (17%) patients experienced serious adverse events. The Italian experience has been recently reported in 37 HCV-Cryovas patients who received DAAs [51]. Ten percent of patients also received immunosuppressants.…”

Section: The Era Of Daa Combinationsmentioning

confidence: 99%

Hepatitis C Virus Infection and Rheumatic Diseases

Cacoub¹,

Commarmond²,

Sadoun³

et al. 2017

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is associated with liver and extrahepatic complications, including B-cell lymphoma, cardiovascular and kidney diseases, glucose metabolism impairment and rheumatic conditions ie, arthralgia, myalgia, cryoglobulinemia vasculitis, sicca syndrome and the production of autoantibodies. The treatment has long been based on interferon alpha (IFN) that was found poorly effective, and contraindicated in many autoimmune/inflammatory disorders because of possible exacerbation of rheumatic disorders. The recent emergence of new oral IFN-free combinations offers an opportunity for HCV infected patients with autoimmune/inflammatory disorders to be cured with a short treatment duration and low risk of side effects.

show abstract

“…6 In large HCV-infected populations, about 50% of patients produce an MC, whereas 15% to 20% experience a symptomatic MC (MC vasculitis). 10,11 Interaction between HCV and lymphocytes directly modulates B-cell and T-cell function and results in polyclonal activation and expansion of B-cellproducing IgM with RF activity. 12 CD4 + CD25 + FoxP3 + regulatory T cells, which have been shown to control autoimmunity, are significantly reduced in patients with HCV-MC vasculitis.…”

Section: Hcv-induced Mixed Cryoglobulinemiamentioning

confidence: 99%

Hepatitis C and Its Relation to B-Cell Lymphoma

2017

Lymphoma and Chronic Lymphocytic Leukemias

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a global health concern, with millions of people chronically infected. The course of this chronic disease may lead to lymphoproliferative disorders ranging from benign mixed cryoglobulinemia to malignant non-Hodgkin lymphoma (NHL). In this article, we reviewed the current knowledge of the different pathologic mechanisms involved in the occurrence of HCV-related lymphoproliferative diseases. Hepatitis C virus directly or indirectly causes different steps of progressive alterations. A chronic antigenic stimulation will select a B-cell clone that will gain immortality via alterations in coding DNA in proto-oncogenes and tumoursuppressor regions. The main challenge in the treatment of HCV-induced NHL is to obtain a sustained virologic response before HCV induced irreversible damages leading to everlasting cell survival. The new interferon-free therapies introduce a new era of management of HCV-NHL, with recent published data to be promising. Nevertheless, further studies are required to assess the safety of those drugs, particularly in association with chemotherapy.

show abstract

HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Cited by 3 publications

References 0 publications

Hepatitis C virus infection and chronic kidney disease: Time for reappraisal

Hepatitis C virus infection and chronic kidney disease: Time for reappraisal

Hepatitis C Virus Infection and Rheumatic Diseases

Hepatitis C and Its Relation to B-Cell Lymphoma

Contact Info

Product

Resources

About